FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and

 FDA Approvals, Stock Price Movements, and Study Results - Research Report on
         Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 21, 2013

NEW YORK, November 21, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Celgene Corporation (NASDAQ: CELG), Merck & Co., Inc. (NYSE:
MRK), Quest Diagnostics Inc. (NYSE: DGX) and Pharmacyclics, Inc. (NASDAQ:
PCYC). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

Pfizer Inc. Research Report

On November 18, 2013, Pfizer Inc. (Pfizer) announced that the U.S. Food and
Drug Administration (FDA) approved the supplemental New Drug Application
(sNDA) for XELJANZ (tofacitinib citrate) to include additional
Patient-Reported Outcomes (PRO) data in the label. According to Pfizer, these
additional data show improvement in patients receiving XELJANZ based on
health-related outcome measures reported by patients, including vitality, role
emotional, physical function, bodily pain, social function, mental health,
role physical and general health, which are the eight domains of the Medical
Outcomes Study Short-Form (36-Item) Health Survey (SF-36). Dr. Steven Romano,
Senior Vice President and Head of the Medicines Development Group for Pfizer
Specialty Care, said, "The patient-reported outcomes data show the impact that
XELJANZ can have on the daily lives of patients with RA, based on physical,
mental and emotional measures. Following the FDA approval of XELJANZ in
November 2012, we are pleased with the agency's decision to approve this sNDA
and add to the growing body of knowledge about XELJANZ as an additional
treatment option for patients with RA." The Full Research Report on Pfizer
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d702_PFE

--

Celgene Corporation Research Report

On November 18, 2013, Celgene Corporation's (Celgene) stock rose 1.24%, ending
the day at $152.98. Over the previous three trading sessions, shares of
Celgene gained 2.48% compared to the Nasdaq Composite which declined 0.42%
during the same period. The Full Research Report on Celgene Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/7f47_CELG

--

Merck & Co., Inc. Research Report

On November 18, 2013, Merck & Co., Inc. (Merck) announced that its New Drug
Application (NDA) for an investigational intravenous (IV) solution formulation
of the Company's antifungal agent, NOXAFIL (posaconazole) has been accepted
for priority review by the U.S. Food and Drug Administration (FDA). According
to the Company, priority review designation is assigned to application for
drugs that, if approved, would provide significant improvements in the safety
and effectiveness of the treatment, diagnosis, or prevention of serious
conditions. In addition, Merck informed that it has filed a marketing
authorization application for NOXAFIL IV solution with the European Medicines
Agency (EMA) and plans to seek regulatory approval for the IV formulation in
other countries around the world. The Full Research Report on Merck & Co.,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/430d_MRK

--

Quest Diagnostics Inc. Research Report

On November 18, 2013, Quest Diagnostics Inc. (Quest Diagnostics) released the
results of a landmark analysis of workplace drug test. According to the
Company, the Drug Testing Index (DTI) examined more than 125 million urine
drug tests performed by the Company's forensic toxicology laboratories across
the United States as a service for government and private employers between
1988 and 2012. The index reported the percentage of results that tested
positive for the presence of a drug or its metabolite, an adulterant or that
involved a specimen that was deemed to be unacceptable for testing
(positivity). The key findings from the analysis released by the Company
suggest that: the positivity rate for the combined U.S. workforce declined 74%
from 13.6% in 1988 to 3.5% in 2012; the positivity rate for the
federally-mandated safety sensitive workforce declined by 38% from 2.6% in
1992 to 1.6% in 2012; and the positivity rate for the U.S. general workforce
declined by 60% from 10.3% in 1992 to 4.1% in 2012. The Full Research Report
on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05ba_DGX

--

Pharmacyclics, Inc. Research Report

On November 13, 2013, Pharmacyclics Inc. (Pharmacyclics) announced that the
U.S. Food and Drug Administration (FDA) has approved IMBRUVICA (ibrutinib) as
a single agent for the treatments of patients with mantle cell lymphoma (MCL)
who have received at least one prior therapy. According to the Company,
IMBRUVICA is a new agent that inhibits the function of Bruton's tyrosine
kinase (BTK), a key signaling molecule of the B-cell receptor signaling
complex that plays an important role in the survival of malignant B cells.
IMBRUVICA blocks signals that stimulate malignant B cells to grow and divide
uncontrollably. Pharmacyclics added that IMBRUVICA is one of the first
treatments to receive FDA approval via the Breakthrough Therapy Designation
pathway and is commercially available now. The Full Research Report on
Pharmacyclics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/df74_PCYC

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)